Cargando…
Tecovirimat for the treatment of severe Mpox in Germany
BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required f...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240449/ https://www.ncbi.nlm.nih.gov/pubmed/37273167 http://dx.doi.org/10.1007/s15010-023-02049-0 |
_version_ | 1785053755057635328 |
---|---|
author | Hermanussen, Lennart Brehm, Thomas Theo Wolf, Timo Boesecke, Christoph Schlabe, Stefan Borgans, Frauke Monin, Malte B. Jensen, Björn-Erik Ole Windhaber, Stefan Scholten, Stefan Jordan, Sabine Lütgehetmann, Marc Wiesch, Julian Schulze zur Addo, Marylyn M. Mikolajewska, Agata Niebank, Michaela Schmiedel, Stefan |
author_facet | Hermanussen, Lennart Brehm, Thomas Theo Wolf, Timo Boesecke, Christoph Schlabe, Stefan Borgans, Frauke Monin, Malte B. Jensen, Björn-Erik Ole Windhaber, Stefan Scholten, Stefan Jordan, Sabine Lütgehetmann, Marc Wiesch, Julian Schulze zur Addo, Marylyn M. Mikolajewska, Agata Niebank, Michaela Schmiedel, Stefan |
author_sort | Hermanussen, Lennart |
collection | PubMed |
description | BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus. METHODS: We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms. RESULTS: A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution. CONCLUSIONS: In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement. |
format | Online Article Text |
id | pubmed-10240449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-102404492023-06-06 Tecovirimat for the treatment of severe Mpox in Germany Hermanussen, Lennart Brehm, Thomas Theo Wolf, Timo Boesecke, Christoph Schlabe, Stefan Borgans, Frauke Monin, Malte B. Jensen, Björn-Erik Ole Windhaber, Stefan Scholten, Stefan Jordan, Sabine Lütgehetmann, Marc Wiesch, Julian Schulze zur Addo, Marylyn M. Mikolajewska, Agata Niebank, Michaela Schmiedel, Stefan Infection Brief Report BACKGROUND: In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus. METHODS: We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms. RESULTS: A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution. CONCLUSIONS: In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement. Springer Berlin Heidelberg 2023-06-05 2023 /pmc/articles/PMC10240449/ /pubmed/37273167 http://dx.doi.org/10.1007/s15010-023-02049-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Brief Report Hermanussen, Lennart Brehm, Thomas Theo Wolf, Timo Boesecke, Christoph Schlabe, Stefan Borgans, Frauke Monin, Malte B. Jensen, Björn-Erik Ole Windhaber, Stefan Scholten, Stefan Jordan, Sabine Lütgehetmann, Marc Wiesch, Julian Schulze zur Addo, Marylyn M. Mikolajewska, Agata Niebank, Michaela Schmiedel, Stefan Tecovirimat for the treatment of severe Mpox in Germany |
title | Tecovirimat for the treatment of severe Mpox in Germany |
title_full | Tecovirimat for the treatment of severe Mpox in Germany |
title_fullStr | Tecovirimat for the treatment of severe Mpox in Germany |
title_full_unstemmed | Tecovirimat for the treatment of severe Mpox in Germany |
title_short | Tecovirimat for the treatment of severe Mpox in Germany |
title_sort | tecovirimat for the treatment of severe mpox in germany |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240449/ https://www.ncbi.nlm.nih.gov/pubmed/37273167 http://dx.doi.org/10.1007/s15010-023-02049-0 |
work_keys_str_mv | AT hermanussenlennart tecovirimatforthetreatmentofseverempoxingermany AT brehmthomastheo tecovirimatforthetreatmentofseverempoxingermany AT wolftimo tecovirimatforthetreatmentofseverempoxingermany AT boeseckechristoph tecovirimatforthetreatmentofseverempoxingermany AT schlabestefan tecovirimatforthetreatmentofseverempoxingermany AT borgansfrauke tecovirimatforthetreatmentofseverempoxingermany AT moninmalteb tecovirimatforthetreatmentofseverempoxingermany AT jensenbjornerikole tecovirimatforthetreatmentofseverempoxingermany AT windhaberstefan tecovirimatforthetreatmentofseverempoxingermany AT scholtenstefan tecovirimatforthetreatmentofseverempoxingermany AT jordansabine tecovirimatforthetreatmentofseverempoxingermany AT lutgehetmannmarc tecovirimatforthetreatmentofseverempoxingermany AT wieschjulianschulzezur tecovirimatforthetreatmentofseverempoxingermany AT addomarylynm tecovirimatforthetreatmentofseverempoxingermany AT mikolajewskaagata tecovirimatforthetreatmentofseverempoxingermany AT niebankmichaela tecovirimatforthetreatmentofseverempoxingermany AT schmiedelstefan tecovirimatforthetreatmentofseverempoxingermany |